CA2648604C — Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
Assigned to Opko Health Inc · Expires 2016-05-24 · 10y expired
What this patent protects
Disclosed are hydrochloride and tosylate crystalline salt forms of (5S,8S)-8- [{(1R)-1 -(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7- diazaspiro[4.5]decan-2-one, represented by Formula I and methods of preparing the same.
USPTO Abstract
Disclosed are hydrochloride and tosylate crystalline salt forms of (5S,8S)-8- [{(1R)-1 -(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7- diazaspiro[4.5]decan-2-one, represented by Formula I and methods of preparing the same.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.